BioNTech (NASDAQ:BNTX) Posts Earnings Results, Misses Expectations By $1.34 EPS

BioNTech (NASDAQ:BNTX) released its quarterly earnings data on Monday. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34), Briefing.com reports. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the prior year, the company posted ($0.86) EPS. The company’s revenue for the quarter was down 23.3% compared to the same quarter last year. BioNTech updated its FY 2024 guidance to EPS.

BioNTech Stock Performance

BNTX opened at $81.29 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. The company has a market capitalization of $19.32 billion, a price-to-earnings ratio of 159.00 and a beta of 0.23. The business’s 50-day moving average price is $87.45 and its two-hundred day moving average price is $90.50. BioNTech has a 1 year low of $76.53 and a 1 year high of $125.83.

Analysts Set New Price Targets

Several research firms have recently issued reports on BNTX. Deutsche Bank Aktiengesellschaft upgraded BioNTech from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research report on Wednesday. BMO Capital Markets lowered their target price on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research note on Tuesday, May 7th. HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. TD Cowen lowered their price objective on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research report on Tuesday. Finally, Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.00.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.